Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

ALT
Altimmune, Inc. Common Stock
stock NASDAQ

At Close
Jun 18, 2025 3:59:59 PM EDT
6.76USD-1.814%(-0.13)5,719,572
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jun 18, 2025 9:25:30 AM EDT
6.89USD0.000%(0.00)12,113
After-hours
Jun 18, 2025 4:57:30 PM EDT
6.78USD+0.222%(+0.02)6,511
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsDividendsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
07:16AM EST  Altimmune: FDA Clears IND Application For Phase 2 Clinical Trial Of Pemvidutide For Obesity   RTTNews
07:06AM EST  Altimmune Announces FDA Clearance Of Pemvidutide (ALT-801) IND For Obesity   Benzinga
07:00AM EST  Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for   GlobeNewswire Inc
Jan 3, 2022
12:11PM EST  Avidity Partners Management Reports In 13G Filing A 7% Stake In Altimmune   Benzinga
07:06AM EST  Altimmune To Present Pemvidutide Clinical Data At Upcoming NASH-TAG Conference January 8, 2022   Benzinga
07:00AM EST  Altimmune to Present Pemvidutide Clinical Data at Upcoming   GlobeNewswire Inc
Dec 13, 2021
06:24AM EST  Biopharmaceutical company Altimmune, Inc. (ALT) announced Monday the appointment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. Eisenstadt succeeds Will Brown, who is leaving Altimmune to pursue other opportunities.   RTTNews
06:09AM EST  Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
06:09AM EST  Altimmune Appoints Richard Eisenstadt As CFO, Effective Dec 31   RTTNews
06:06AM EST  Altimmune Appoints Richard Eisenstadt As CFO   Benzinga
06:00AM EST  Altimmune Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
06:00AM EST  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, today announced the appointment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. Mr. Eisenstadt succeeds Will Brown, who is leaving Altimmune to pursue other opportunities.   GlobeNewswire Inc
Nov 22, 2021
04:01PM EST  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companys management team will be presenting virtually at the following conferences:   GlobeNewswire Inc
Nov 10, 2021
04:01PM EST  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companys management team will be presenting virtually at the following investor conferences in November 2021:   GlobeNewswire Inc
Nov 9, 2021
04:47PM EST  Altimmune Q3 EPS $(0.81) Down From $(0.54) YoY, Sales $200.00K Down From $2.94M YoY   Benzinga
Nov 3, 2021
04:01PM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021.   GlobeNewswire Inc
Oct 12, 2021
07:39AM EDT  Altimmune Granted U.S. Patent #11,141,477 'Rapid and prolonged immunologic-therapeutic'   Benzinga
Oct 11, 2021
03:51PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (Altimmune or the Company) (NASDAQ:ALT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Oct 6, 2021
04:03PM EDT  Altimmune To Present At Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021   Benzinga
04:01PM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences:   GlobeNewswire Inc
Oct 4, 2021
07:24AM EDT  Altimmune Begins 12-week Phase 1b Trial Of Pemvidutide In Subjects With Non-Alcoholic Fatty Liver Disease   RTTNews
07:04AM EDT  Altimmune Announces Initiation Of 12-week Phase 1b Trial Of Pemvidutide In Subjects With Non-Alcoholic Fatty Liver Disease   Benzinga
07:00AM EDT  -- First patient has been enrolled in 12-week non-alcoholic fatty liver disease (NAFLD) study -- Dr. Stephen Harrison will be serving as Principal Investigator for the study -- Topline data readout expected in the first half of 2022   GlobeNewswire Inc
Oct 3, 2021
08:53PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (Altimmune or the Company) (NASDAQ:ALT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Sep 30, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
Sep 29, 2021
06:15PM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its 12-week Phase 1 clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in overweight and obese subjects on Thursday, September 30, 2021 at 9:00 am EST.   GlobeNewswire Inc
Sep 28, 2021
12:00PM EDT  Watching Altimmune Shares; Piper-Sandler Sets $34 Price Target   Benzinga
10:52AM EDT  Shares of Altimmune, Inc. (ALT) tanked over 20% on Tuesday morning after announcing 12-week data from Phase 1 trial for weight loss therapy.   RTTNews
09:39AM EDT  Altimmune Option Alert: Dec 17 $22 Calls Sweep (24) above Ask!: 750 @ $0.9 vs 915 OI; Earnings 11/8 After Close [est] Ref=$12.385   Benzinga
08:18AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments   Benzinga
08:10AM EDT  Altimmune Inc. (ALT) said that mean weight loss of 10.3% achieved in subjects receiving 1.8 mg dose of pemvidutide, as per phase 1 clinical trial of pemvidutide or ALT-801 in overweight and obese subjects.   RTTNews
07:28AM EDT  Altimmune Announces Positive Results From 12-week Phase 1 Trial Of Pemvidutide In Overweight And Obese Volunteers   RTTNews
07:07AM EDT  Altimmune Announces Results From 12-week Phase 1 Clinical Trial Of ALT-801 In Overweight And Obese Volunteers; Mean Weight Loss Of 10.3%   Benzinga
07:01AM EDT  -- Mean weight loss of 10.3% achieved in subjects receiving 1.8 mg dose -- Pemvidutide was well-tolerated without the need for dose titration -- No discontinuations due to treatment-emergent adverse events -- NASH IND has cleared FDA review; 12-week NAFLD study to begin in the near future -- Altimmune to host a conference call today at 8:30 am EST   GlobeNewswire Inc
Sep 27, 2021
05:03PM EDT  Biopharmaceutical company Altimmune, Inc. (ALT) on Monday announced that the company will report results from a Phase 1 clinical trial of ALT-801 in overweight and obese subjects.   RTTNews
04:02PM EDT  Altimmune To Announce 12-Week Data From ALT-801 Phase 1 Trial On Sept. 28   Benzinga
04:01PM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of ALT-801 in overweight and obese subjects in a pre-market press release and webcast to be held on Tuesday, September 28, 2021.   GlobeNewswire Inc
Sep 8, 2021
11:21AM EDT  Altimmune Option Alert: Dec 17 $22 Calls Sweep (6) near the Ask: 100 @ $3.0 vs 6 OI; Ref=$16.57   Benzinga
Sep 7, 2021
04:01PM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually onSeptember 13-15, 2021.   GlobeNewswire Inc
Aug 26, 2021
09:39AM EDT  USPTO Site Shows Altimmune Application For Patent 'Coronavirus Immunogenic Compositions And Uses Thereof'   Benzinga
Aug 16, 2021
11:26AM EDT  Altimmune Sponsored Study ALT-801 In Diabetic And Non-Diabetic Overweight And Obese Subjects With Non-alcoholic Fatty Liver Disease Posted To clinical Trials Website Not Yet Recruiting   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
04:11PM EDT  Altimmune Q2 EPS $(0.60) Up From $(0.94) YoY, Sales $137.62K Down From $721.64K YoY   Benzinga
04:01PM EDT  12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September   GlobeNewswire Inc
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 4, 2021
04:01PM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021.   GlobeNewswire Inc
Jul 22, 2021
12:36PM EDT  Altiumme National Institutes Of Health ClinicalTrials.gov Listing For Co.'s 'The Effect of ALT-801 on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin, Digoxin, and the Combined Oral Contraceptive...' Shows Not Yet Recruiting   Benzinga
Jul 20, 2021
11:13AM EDT  Altimmune Granted U.S. Patent Titled 'Antigen delivery vectors and constructs'   Benzinga
Jul 11, 2021
04:41PM EDT  Cramer Gives His Opinion On AT&T, Cemex And More   Benzinga
Jun 30, 2021
02:36PM EDT  Mid-Afternoon Market Update: Dow Jumps 190 Points; Altimmune Shares Plummet   Benzinga
12:23PM EDT  Mid-Day Market Update: Barnes & Noble Education Drops Following Q4 Results; Aerovate Therapeutics Shares Surge   Benzinga
10:52AM EDT  Mid-Morning Market Update: Markets Mostly Higher; General Mills Beats Q4 Views   Benzinga
09:06AM EDT  B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $21   Benzinga
08:06AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
07:29AM EDT  The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs   Benzinga
06:56AM EDT  JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $31   Benzinga
06:25AM EDT  HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $25   Benzinga
06:16AM EDT  Altimmune Stock Tanks On Double Bad News From COVID-19 Program   Benzinga
Jun 29, 2021
05:24PM EDT  Shares of Altimmune Inc. (ALT) plunged 35% in extended session on Tuesday after the clinical-stage biopharmaceutical company said that its stopping development of its investigational Covid-19 vaccine AdCOVID.   RTTNews
05:11PM EDT  Altimmune Announces Update On AdCOVID Phase 1 Clinical Trial   RTTNews
04:07PM EDT  Altimmune Says Has Been Unable To enroll Subjects In Final Cohort Of T-COVID Study, Will Terminate Further Enrollment And Evaluate Options For T-COVID   Benzinga
04:04PM EDT  Altimmune Shares To Resume Trade At 4:30 p.m. EDT   Benzinga
04:02PM EDT  Altimmune To Discontinue further Development Of AdCOVID And Focus Resources On Obesity And Liver Programs   Benzinga
04:01PM EDT  -- AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteers -- Altimmune will discontinue further development of AdCOVID and focus its resources on its ongoing obesity and liver programs -- Altimmune also provides an update on its T-COVIDPhase 1/2 Clinical Trial   GlobeNewswire Inc
04:01PM EDT  Altimmune Shares Halted News Pending   Benzinga
Jun 16, 2021
01:13PM EDT  JMP Securities Maintains Market Outperform on Altimmune, Raises Price Target to $53   Benzinga
12:33PM EDT  Altimmune Shares Move Higher On Volume; JP Morgan Raises Price Target To Street High Of $53   Benzinga
08:20AM EDT  The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO   Benzinga
07:28AM EDT  Altimmune's ALT-801 Achieves 5.4% Weight Loss Surpassing Pre-Established Target Of 2%   Benzinga
07:13AM EDT  Altimmune Announces Positive Interim Data From ALT-801 Phase 1 Trial In Healthy Overweight And Obese Volunteers   RTTNews
07:02AM EDT  Altimmune Announces Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers; Weight Loss Of 5.4% Achieved At 6 Weeks With 1.8 mg Once Weekly Dose   Benzinga
07:00AM EDT  Altimmune Announces Positive Interim Data from ALT-801 Phase 1   GlobeNewswire Inc
Jun 2, 2021
10:24AM EDT  A Peek Into The Markets: US Stock Futures Mixed Ahead of Fed Minutes   Benzinga
10:10AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2021   Benzinga
06:09AM EDT  A Peek Into The Markets: US Stock Futures Mixed Ahead of ADP Report, Fed Minutes   Benzinga
06:06AM EDT  HC Wainwright & Co. Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $35   Benzinga
May 27, 2021
07:00AM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the 2021 Jefferies Virtual Healthcare Conference, being held June 1 - 4, 2021.   GlobeNewswire Inc
May 26, 2021
09:29AM EDT  Altimmune Inc.'s (ALT) AdCOVID vaccine candidate could neutralize the rapidly emerging SARS-CoV-2 B.1.351 variant of concern that originated in South Africa, as per a preclinical study.   RTTNews
09:09AM EDT  Altimmune's Intranasal COVID-19 Vaccine Candidate Neutralizes South African Variant, Animal Study Shows   Benzinga
07:33AM EDT  The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing   Benzinga
07:12AM EDT  Altimmune Announces Preclinical Results From Phase I Study Of AdCOVID; Says Similar Neutralization Titers Observed For Both Ancestral And B.1.351 South African Variant   Benzinga
07:11AM EDT  Altimmune: Preclinical Study Show AdCOVID Vaccine Candidate Neutralization Of South African Variant   RTTNews
07:00AM EDT  Similar Neutralization Titers Observed for Both Ancestraland B.1.351 South African Variant   GlobeNewswire Inc
May 17, 2021
01:22PM EDT  Looking Into Altimmune's Return On Capital Employed   Benzinga
07:20AM EDT  Altimmune Q1 EPS $(0.38) Beats $(0.47) Estimate, Sales $837.52K Down From $2.21M YoY   Benzinga
07:00AM EDT  Data Readouts from Phase 1 AdCOVID and ALT-801 Clinical Trials Expected in June   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For May 17, 2021   Benzinga
May 11, 2021
07:00AM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021.   GlobeNewswire Inc
May 10, 2021
09:10AM EDT  Altimmune's Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity After Single Dose   Benzinga
07:07AM EDT  Altimmune Announces its AdCOVID Showed Sterilizing Immunity in the Lungs of Vaccinated Mice After a Single Intranasal Dose   Benzinga
07:00AM EDT  Data Show No Detectable Levels of Infectious Virus in Lungs of Vaccinated Mice Following Challenge with SARS-CoV-2   GlobeNewswire Inc
Apr 29, 2021
07:00AM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companys management team will be presenting at two scientific conferences in May 2021.   GlobeNewswire Inc
Apr 16, 2021
03:50PM EDT  AVG Group Sarl Takes Strategic Investment in Alternus Energy Group PLC   PR Newswire
Apr 1, 2021
09:37AM EDT  Altimmune's Anthrax Vaccine Candidate Shows Early Safety, Immunogenicity In Healthy Volunteers   Benzinga
07:04AM EDT  Altimmune Reports Data From Its Phase 1b Clinical Trial Of NasoShield   Benzinga
07:00AM EDT  Altimmune Reports Data from its Phase 1b Clinical Trial of   GlobeNewswire Inc
Mar 22, 2021
07:08AM EDT  Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID Vaccine Candidate   Benzinga
07:00AM EDT  Altimmune Partners with Summit Biosciences to Produce a Multidose   GlobeNewswire Inc
Mar 15, 2021
07:58AM EDT  Altimmune's Shares Are Trading Higher On Intranasal COVID-19 Vaccine Candidate's Promising Action In Animal Studies   Benzinga
07:02AM EDT  Altimmune Announces Preclinical Data Showing Its AdCOVID COVID-19 Vaccine Candidate Showed 'Complete Protection Against Lethal Challenge and Dramatic Reduction in Viral Replication'   Benzinga
07:00AM EDT  New Findings from Ongoing Collaborations with University of Alabama at Birminghamand Saint Louis University   GlobeNewswire Inc
Mar 12, 2021
07:36AM EST  The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs   Benzinga
06:10AM EST  Altimmune Shares Are Trading Higher On Expanded Manufacturing Pact With Lonza   Benzinga
05:51AM EST  Altimmune Earlier Reported Expansion of AdCOVID Manufacturing Collaboration with Lonza; Shares Up 30% Premarket   Benzinga
01:00AM EST  Altimmune Expands AdCOVID Manufacturing   GlobeNewswire Inc
Mar 8, 2021
04:01PM EST  Altimmune to Present at Upcoming Conferences   GlobeNewswire Inc
Feb 25, 2021
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
07:04AM EST  Altimmune Says Enrollment In Phase 1 AdCOVID Clinical Trial Has Commenced   Benzinga
07:03AM EST  Altimmune FY 2020 EPS $(1.91) Vs $(2.59) Est   Benzinga
07:03AM EST  Nasal spray may offer room temperature distribution that could reduce logisticalchallenges for healthcare systems and providers   GlobeNewswire Inc
07:00AM EST  Altimmune Announces Financial Results for the Year Ended December   GlobeNewswire Inc
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 22, 2021
04:30PM EST  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.   GlobeNewswire Inc
Feb 17, 2021
09:06AM EST  Altimmune's AdCOVID Vaccine Gets Positive FDA Update   Benzinga
07:10AM EST  Altimmune Announces FDA Clearance Of AdCOVID IND Application   Benzinga
07:10AM EST  Altimmune Announces FDA Clearance of AdCOVID IND   GlobeNewswire Inc
Jan 4, 2021
09:46PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of   PR Newswire
Dec 30, 2020
08:20AM EST  Altimmune Announced That It Has Announced That It Has Enrolled The First Patient In Its Multinational Phase 2 Clinical Trial Of HepTcell   Benzinga
08:18AM EST  Altimmune Begins Phase 2 Clinical Trial Of HepTcell -   RTTNews
08:14AM EST  Altimmune Enrolls First Patient In Its Multinational Phase 2 Clinical Trial Of HepTcell   RTTNews
08:00AM EST  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its multinational Phase 2 clinical trial of HepTcell, a novel peptide-based immunotherapeutic under development for treatment of chronic hepatitis B (CHB).   GlobeNewswire Inc
Dec 26, 2020
09:16AM EST  The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks   Benzinga
Dec 24, 2020
10:05AM EST  Shares of clinical-stage bio pharmaceutical company Altimmune, Inc. (ALT) are down more than 6% Thursday morning after the company said that the FDA has issued a clinical hold on the Investigational New Drug (IND) application for its Covid-19 vaccine candidate, AdCOVID.   RTTNews
06:32AM EST  A Peek Into The Markets: US Stock Futures Up Ahead Of Christmas Break   Benzinga
Dec 23, 2020
05:42PM EST  Fuwei Films (Holdings) Co., Ltd. (FFHL) - Shares of the Chinese PET film maker gained 16% in after hours trading on top of 23% gain in regular trading. Fuwei Films announced that the open bidding initiated to sell its Dornier production line resulted in a successful bid. Huizhou Yidu Yuzheng Digital Technology won the bidding at a price of RMB138.0 million or about $21.07 million.   RTTNews
04:01PM EST  Altimmune Announces FDA Has Issued Clinical Hold On Co's Investigational New Drug Application For AdCOVID   Benzinga
04:01PM EST  Altimmune Provides an Update on its Investigational New Drug   GlobeNewswire Inc
Dec 11, 2020
07:00AM EST  Altimmune to Present at the 4th Annual NASH Summit 2020 Digital   GlobeNewswire Inc
Dec 8, 2020
08:00AM EST  Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a   GlobeNewswire Inc
Nov 25, 2020
07:36AM EST  Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, said Wednesday that it has submitted an Investigational New Drug or IND application to the U.S. Food and Drug Administration (FDA) to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.   RTTNews
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
07:14AM EST  Altimmune Submits IND Application For AdCOVID A Single-dose Intranasal COVID-19 Vaccine   RTTNews
07:01AM EST  Altimmune Announces Submission Of Investigational New Drug Application For AdCOVID Single-Dose Intranasal COVID-19 Vaccine; On Track To Commence Phase 1 Clinical Study In December   Benzinga
07:00AM EST  Simple, single-dose nasal spray offers greater ease and comfort of administration;positioning AdCOVID as a differentiated vaccine candidate for adults and children   GlobeNewswire Inc
Nov 24, 2020
08:08AM EST  Evercore ISI Group Reinstates Outperform on Altimmune, Announces $25 Price Target   Benzinga
Nov 16, 2020
10:02AM EST  Altimmune, Inc. (ALT) shares are declining more than 8 percent on Monday morning, as the stock is in search of new support.   RTTNews
07:00AM EST  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences:   GlobeNewswire Inc
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
01:00AM EST  AdCOVID, a Single-dose Intranasal Vaccine for COVID-19is Designed to Generate aBroad Immune Response Against COVID-19 with the Unique Ability to PromoteNasal Mucosal Immunity   GlobeNewswire Inc
Nov 9, 2020
04:22PM EST  Altimmune Q3 EPS $(0.54) Beats $(0.76) Estimate   Benzinga
04:05PM EST  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2020 and provided a business update.   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 3, 2020
08:00AM EST  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.   GlobeNewswire Inc
Oct 15, 2020
07:00AM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences:   GlobeNewswire Inc
Oct 13, 2020
12:18PM EDT  Mid-Day Market Update: Gold Down 2%; Medigus Shares Spike Higher   Benzinga
10:14AM EDT  Shares of Altimmune Inc. (ALT) are gaining more than 19 percent or $2.43 in Tuesday's morning trade at $15.03.   RTTNews
10:11AM EDT  Mid-Morning Market Update: Markets Down; JPMorgan Profit Beats Estimates   Benzinga
09:44AM EDT  ROCE Insights For Altimmune   Benzinga
Oct 12, 2020
07:53AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Monday, Oct. 12, 2020: SPTN, TACO, HUYA, APDN, ALT   Benzinga
07:03AM EDT  Altimmune Publishes Pre-Clinical Data on its COVID-19 Vaccine Candidate   Benzinga
07:01AM EDT  Comprehensive analysis shows AdCOVID uniquelystimulates three key immune components: serum neutralizing antibody, T cell responses, and mucosal immunity in the respiratory tract   GlobeNewswire Inc
Oct 6, 2020
05:16PM EDT  IIROC Trading Resumption - ALT   PR Newswire
Sep 30, 2020
07:00AM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October:   GlobeNewswire Inc
Sep 28, 2020
04:02PM EDT  Altimmune To Present Highlights Of Intranasal COVID-19 Vaccine And Therapeutic Programs AdCOVID And T-COVID At World Vaccine Congress Sept. 21-Oct. 1   Benzinga
04:01PM EDT  Altimmune Presents Highlights of Intranasal COVID-19 Vaccine and   GlobeNewswire Inc
Sep 25, 2020
12:24PM EDT  B. Riley FBR Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $31   Benzinga
10:42AM EDT  Shares of clinical stage biopharmaceutical company, Altimmune, Inc. (ALT) are climbing more than 10% Friday morning at $13.33. It has traded in the range of $1.51- $35.10 in the past 52 weeks.   RTTNews
Sep 24, 2020
04:16PM EDT  D.E. Shaw & Co. Reports 5% Passive Stake In Altimmune   Benzinga
Sep 14, 2020
10:57AM EDT  While there are no particular company-specific news reported today, Shares of Altimmune, Inc. (ALT) are currently gaining nearly 10%. ALT is currently trading at $13.25, up $1.16 or 9.59%, on the Nasdaq.   RTTNews
Sep 1, 2020
07:17AM EDT  Altimmune Announces Completion Of Multiple Dose Toxicity, Toxicokinetic Studies Of ALT-801   RTTNews
07:03AM EDT  Altimmune Announces Completion Of Multiple Dose Toxicity And Toxicokinetic Studies Of ALT-801, A GLP-1/Glucagon Dual Receptor Agonist For The Treatment Of NASH; Company Anticipates First-In-Human Trials To Start In Q4 2020   Benzinga
07:00AM EDT  Altimmune Announces Successful Completion of Multiple Dose   GlobeNewswire Inc
Aug 26, 2020
07:03AM EDT  Altimmune Announces Preclinical Data Presentation On ALT-801   RTTNews
07:00AM EDT  Altimmune Announces Data Presentation on ALT-801, its Balanced and   GlobeNewswire Inc
Aug 25, 2020
11:32AM EDT  Altimmune shares are trading higher after the company, and the University of Alabama at Birmingham, announced "potent respiratory mucosal T Cell responses" in a preclinical study of its Covid-19 vaccine candidate, AdCOVID.   Benzinga
07:04AM EDT  Altimmune And University Of Alabama At Birmingham Announce 'Potent Respiratory Mucosal T Cell Responses' In Preclinical Study Of Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID   Benzinga
07:00AM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced additional positive results from the preclinical studies of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID. The studies were conducted as part of Altimmunes ongoing collaboration with the University of Alabama at Birmingham (UAB).   GlobeNewswire Inc
02:30AM EDT  Altran Enhances Its ENSCONCE Edge Computing Platform   GlobeNewswire Inc
Aug 20, 2020
09:37AM EDT  Alpha Investment Shares Spike Higher As Traders Circulate Pre-Proof Draft Of Journal Publication Providing Preclinical Validation For Co's Mucosal Vaccine Platform   Benzinga
Aug 12, 2020
10:50AM EDT  Altimmune shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results. UPDATE: Shares have since reversed, now higher.   Benzinga
Aug 11, 2020
07:15PM EDT  Recap: Altimmune Q2 Earnings   Benzinga
04:29PM EDT  Altimmune Q2 EPS $(0.94) Misses $(0.40) Estimate, Sales $700.00K Miss $1.10M Estimate   Benzinga
04:05PM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2020 and provided a business update.   GlobeNewswire Inc
Aug 7, 2020
07:22AM EDT  Altimmune Completes Enrollment In Phase 1b Clinical Trial Of NasoShield, A Single Dose Intranasal Anthrax Vaccine Candidate   Benzinga
07:15AM EDT  Altimmune Completes Enrollment In Its Phase 1b Clinical Trial Of NasoShield   RTTNews
07:00AM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. With this milestone, the data readout for the Day 28 immunogenicity endpoint remains on target for Q4 2020.   GlobeNewswire Inc
Aug 5, 2020
07:00AM EDT  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the three and six months ended June 30, 2020 and its business outlook before the market open and host a conference call on Wednesday, August 12, 2020.   GlobeNewswire Inc
Jul 31, 2020
01:02PM EDT  Piper Sandler Initiates Coverage On Altimmune with Overweight Rating, Announces Price Target of $80   Benzinga
Jul 30, 2020
05:16PM EDT  Hearing Pipier Sandler Initiated Coverage On Altimmune With Overweight Rating, $80 Price Target   Benzinga
Jul 28, 2020
09:37AM EDT  Benzinga's Top Upgrades, Downgrades For July 28, 2020   Benzinga
07:24AM EDT  JMP Securities Initiates Coverage On Altimmune with Market Outperform Rating, Announces Price Target of $50   Benzinga
Jul 22, 2020
07:31AM EDT  Altimmune Announces Manufacturing Agreement With Vigene Biosciences For AdCOVID, Its Single Dose Intranasal Vaccine Candidate For COVID-19   Benzinga
07:30AM EDT  Altimmune Announces Manufacturing Agreement with Vigene   GlobeNewswire Inc
Jul 20, 2020
03:46PM EDT  Shares of several coronavirus vaccine companies are trading lower after early results of AstraZeneca & Oxford University's coronavirus vaccine were released.   Benzinga
Jul 17, 2020
02:30AM EDT  QNAP Chooses Altrans Intelligent Switching   GlobeNewswire Inc
Jul 16, 2020
04:01PM EDT  Altimmune Announces Closing of $132 Million Public Offering of   GlobeNewswire Inc
Jul 15, 2020
04:49AM EDT  55 Biggest Movers From Yesterday   Benzinga
Jul 14, 2020
06:01AM EDT  A Peek Into The Markets: US Stock Futures Up; Bank Earnings In Focus   Benzinga
05:34AM EDT  Altimmune Prices 3.3M Share Public Offering of Common Stock @$23/Share and Pre-Funded Warrants @$22.999/Underlying Share   Benzinga
05:11AM EDT  80 Biggest Movers From Yesterday   Benzinga
Jul 13, 2020
09:41PM EDT  Altimmune Announces Pricing of a Public Offering of $115 Million   GlobeNewswire Inc
04:01PM EDT  Altimmune Announces Proposed Public Offering of Common Stock; Terms Not Disclosed   Benzinga
04:01PM EDT  Altimmune Announces Proposed Public Offering of Common Stock and   GlobeNewswire Inc
09:24AM EDT  Shares of Altimmune Inc. (ALT) are rallying over 22% in pre-market today, after the company announced positive results from the preclinical studies of its intranasal COVID-19 vaccine candidate, AdCOVID.   RTTNews
07:02AM EDT  Altimmune Announces Positive Preclinical Results for its COVID-19 Vaccine Candidate, Altimmune Expects a Phase 1 Study in Q4   Benzinga
07:00AM EDT  Altimmune and the University of Alabama at Birmingham (UAB)   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC